DELLPHI-304
Start here
An interview with Professor Chen Xiao focuses on the mechanism, efficacy, and safety of tarlatamab in second-line small cell lung cancer. Its DLL3/CD3 bispecific T-cell engager (TCE) mechanism bypasses MHC-I restriction. In DeLLphi-304, median OS rose from 8.3 months with chemotherapy to 13.6 months, ORR from 20% to 35%, and the risk of death fell by 40%; the Chinese bridging study DeLLphi-307 showed an ORR of 39%.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comProfessor Chen Xiao Interprets Tarlatamab Second-Line Small Cell Lung Cancer Data and Safety Management
An interview with Professor Chen Xiao focuses on the mechanism, efficacy, and safety of tarlatamab in second-line small cell lung cancer. Its DLL3/CD3 bispecific T-cell engager (TCE) mechanism bypasses MHC-I restriction. In DeLLphi-304, median OS rose from 8.3 months with chemotherapy to 13.6 months, ORR from 20% to 35%, and the risk of death fell by 40%; the Chinese bridging study DeLLphi-307 showed an ORR of 39%.
- mp.weixin.qq.comProfessor Yin Xiaojian discusses tarlatamab in small cell lung cancer: clinical use, access and future development
Professor Yin Xiaojian discusses tarlatamab's clinical use after its approval in China, covering second-line efficacy in SCLC, safety management, payment access and earlier-line exploration. DeLLphi-304 showed tarlatamab extended median OS in second-line patients from 8.3 months with chemotherapy to 13.6 months, reducing death risk by 40% (HR=0.60). The drug received third-line and second-line approvals in April and May 2026, and Fujian's Huiminbao 2026 included it in its high-cost drug reimbursement list.
Heat trend for this story
Heat now 16·Peak in the comparable set 33 (Oct 23 21:00)·Change over 24h in the comparable set -25%·Participants now 5
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.